The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
The Foreign Secretary said "good connections" were important, and suggested the Channel Tunnel might simply be "a first step."
When Arunachalam Muruganatham discovered his wife collecting filthy rags and newspapers to use during her period he felt compelled to act.
A plane which skidded off a runway and down a steep embankment in Turkey has been recovered as investigations get underway.